Oncology · 4 h ago
Dinutuximab With Induction Chemotherapy Feasible in High-Risk Neuroblastoma Pilot
A prospective, single-arm Children’s Oncology Group pilot study evaluated dinutuximab with induction chemotherapy in 40 children with newly diagnosed high-risk neuroblastoma. The regimen met the study’s feasibility and tolerability criteria; a randomized phase III trial is evaluating the approach.
- Pilot enrolled 40 patients at eight sites.
- No unacceptable toxicities or toxic deaths occurred.
- Patients received 92.0%–101.8% of planned dinutuximab doses.
- A randomized phase III trial is evaluating the approach.
The multicenter COG ANBL17P1 pilot study assessed whether dinutuximab (DIN) and sargramostim could be given with induction chemotherapy cycles 3–5 for newly diagnosed high-risk neuroblastoma. Forty eligible patients enrolled at eight sites between January 2019 and June 2020. The primary endpoints were tolerability, defined by predefined unacceptable toxicity or toxic death, and feasibility, defined as receipt of at least 75% of planned DIN doses.
There were no unacceptable toxicities or toxic deaths during DIN-containing cycles. The most common DIN-related grade 3 or higher toxicities were fever (30.0%) and pain (7.5%). Patients received 92.0%–101.8% of intended induction DIN doses. Among 37 patients with all end-of-induction evaluations, 13 had a complete response and 22 a partial response; the reported complete or partial response rate was 87.5%. Three-year event-free survival was 52.5% ± 7.9%.
The authors concluded that adding DIN during these induction cycles was feasible and tolerable. This was a limited, single-arm pilot, and the response and survival findings do not establish comparative benefit. The approach is being evaluated in a COG randomized phase III trial.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Journal of Clinical Oncology: Feasibility and Tolerability of Chemoimmunotherapy Given During Induction for Treatment of Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology Group ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.